Use of Hydroxyurea and Magnesium Pidolate for Treatment of Sickle Cell Disease

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

16 participants

Study Classification

INTERVENTIONAL

Study Start Date

2004-11-30

Study Completion Date

2008-01-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to estimate the MTD of Mg pidolate in combination with HU in patients with sickle cell disease who have been on a therapeutic dose (15-30 mg/kg/day) of HU for at least 6 months.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Hydroxyurea and Magnesium Pidolate to Treat People With Hemoglobin Sickle Cell Disease

NCT00532883

Hemoglobin SC Disease

TERMINATED PHASE2

Oral Magnesium Pidolate, Hemoglobin SC Disease, MG Pidolate

NCT00040456

HEMOGLOBIN SC DISEASE

TERMINATED PHASE2

Long Term Effects of Hydroxyurea Therapy in Children With Sickle Cell Disease

NCT00305175

Sickle Cell Disease

COMPLETED

Predictors and Outcomes in Patients With Sickle Cell Disease

NCT03431935

Sickle Cell Disease

ACTIVE_NOT_RECRUITING

Dipyridamole/Magnesium To Improve Sickle Cell Hydration

NCT00276146

Anemia, Sickle Cell

WITHDRAWN PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This is a Phase I clinical trial evaluating the combination of hydroxyurea and magnesium pidolate for patients with sickle cell disease with either hemoglobin SS disease or hemoglobin S beta thalassemia. Hydroxyurea and magnesium pidolate will be tested in pediatric and adolescent patients with sickle cell disease who already have been treated with hydroxyurea for a minimum of six months. Magnesium pidolate will be given in combination with hydroxyurea for six months. In successive small groups of patients, the dose of magnesium will be increased in order to eventually determine the maximum tolerated dose (MTD) and dose limiting toxicity (DLT) for magnesium when given in combination with hydroxyurea. The maximum tolerated dose is the highest drug dose that can be given safely to participants. The dose limiting toxicity is determined when drug side effects prevent an increase in dose.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Anemia, Sickle Cell

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

1

Group Type OTHER

Magnesium Pidolate, Hydroxyurea

Intervention Type DRUG

Intervention Description: Mg pidolate in combination with HU in patients with sickle cell disease who have been on a therapeutic dose (15-30 mg/kg/day) of HU for at least 6 months. Mg pidolate will be given at an initial dose of 0.6 mEq/kg/day divided into 2 daily doses for the first cohort of patients. This dose will be escalated for the subsequent patient cohorts as defined by a classic Phase I design (according to toxicity).

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Magnesium Pidolate, Hydroxyurea

Intervention Description: Mg pidolate in combination with HU in patients with sickle cell disease who have been on a therapeutic dose (15-30 mg/kg/day) of HU for at least 6 months. Mg pidolate will be given at an initial dose of 0.6 mEq/kg/day divided into 2 daily doses for the first cohort of patients. This dose will be escalated for the subsequent patient cohorts as defined by a classic Phase I design (according to toxicity).

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Age \> 3 years and \< 15 years at the time of study enrollment
2. Diagnosis of Hb SS or Hb S beta thalassemia
3. Hydroxyurea treatment for at least 6 months prior to study entry at dose of 15 - 30 mg/kg/day
4. Compliance with taking HU treatment of at least 70 % for 6 months prior to study entry

Exclusion Criteria

1. Red blood cell transfusion within the last 3 months resulting in a level of Hb A of 10% or more
2. Pregnancy or unwillingness to use effective birth control in sexually active subjects (females who state that they are sexually active)
3. Renal dysfunction defined by a serum creatinine greater than 1.5 times the upper limit of normal for age
4. Liver dysfunction defined by an ALT greater than twice the upper limit of normal for age
5. Concomitant usage of an "antisickling" agent other than hydroxyurea
6. Current use of Mg containing drugs
7. Iron deficiency, defined by serum ferritin ≤ 10 ng/ml
8. Concomitant chronic illness other than sickle cell anemia

Minimum Eligible Age

3 Years

Maximum Eligible Age

15 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No